Genmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024. In the quarter to June 2026, revenue grew 24.9%, EPS fell 9.26% and free cash flow fell 7.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow GMAB
Genmab A/S Sponsored ADR (GMAB) P/E ratio
As of 16 October 2026, Genmab A/S Sponsored ADR (GMAB) trades at a P/E ratio of 29.1×. Over the past ten years it has ranged from 2.1× (October 2018) to 78.6× (September 2021); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 19.9× | 68.53% |
| FY2024 | 11.8× | (64.38%) |
| FY2023 | 33.1× | (9.22%) |
| FY2022 | 36.5× | (31.79%) |
| FY2021 | 53.5× | 44.63% |
| FY2020 | 37.0× | 10.20% |
| FY2019 | 33.5× | 333.68% |
| FY2018 | 7.7× | 158.55% |
| FY2017 | 3.0× | (51.07%) |
| FY2016 | 6.1× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 21.6× | 6.42% |
| Mar 2026 | 20.3× | 2.29% |
| Dec 2025 | 19.9× | 52.90% |
| Sep 2025 | 13.0× | 25.81% |
| 27 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | n/m |
| BNTX BioNTech SE Sponsored ADR compare | n/m |
| INSM Insmed, Inc. compare | n/m |
| INCY Incyte Corporation compare | 13.9× |
| ASND Ascendis Pharma A/S compare | 16.3× |
| EXEL Exelixis, Inc. compare | 18.8× |
| GMAB Genmab A/S Sponsored ADR | 29.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 39.5× |
| RPRX Royalty Pharma PLC compare | 42.3× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)